P/E ratio for Halozyme Therapeutics (HALO)
P/E ratio as of March 2023 (TTM): 24.7
According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.6993. At the end of 2021 the company had a P/E ratio of 14.1.
P/E ratio history for Halozyme Therapeutics from 2004 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 14.1 | -68.29% |
| 2020 | 44.5 | -225.46% |
| 2019 | -35.5 | 33.31% |
| 2018 | -26.6 | -152.52% |
| 2017 | 50.7 | -515.25% |
| 2016 | -12.2 | -81.7% |
| 2015 | -66.7 | 279.89% |
| 2014 | -17.5 | -14.56% |
| 2013 | -20.5 | 49.95% |
| 2012 | -13.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.2 | -10.00% | 🇺🇸 USA |
 Pfizer PFE | 7.14 | -71.09% | 🇺🇸 USA |
 Eli Lilly LLY | 50.3 | 103.65% | 🇺🇸 USA |
 Sanofi SNY | 19.0 | -22.89% | 🇫🇷 France |
 Baxter BAX | -8.26 | -133.43% | 🇺🇸 USA |
 MannKind Corp MNKD | -11.8 | -147.87% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.